Discontinue or reduce dose if an excessive increase in pulse rate is observed in patients w/ coronary artery stenosis. Discontinue if there is clinical or lab evidence of hematological abnormalities. Stabilize patients w/ cerebral infarction prior to use. Patients during menstruation; w/ complication of coronary artery stenosis; DM or abnormal glucose tolerance; HTN w/ consistently high BP eg, malignant HTN; ventricular transposition, tachycardia & fibrillation, atrial transposition, fibrillation & flutter, multifocal ventricular ectopics & prolongation of the QTc interval; risk of sigmoid-shaped interventricular septum. Closely monitor patients for any anginal symptoms eg, chest pain; development of a new systolic murmur or cardiac symptoms after starting treatment. Perform full blood count if infection is suspected or if there is any other clinical evidence of blood dyscrasia. Concomitant use w/ anticoagulants, antiplatelet drugs, thrombolytic drugs, prostaglandin E or its derivatives. Increased lovastatin AUC. May cause dizziness thus caution in driving or operating machinery. Severe renal failure (CrCl 25 mL/min). Moderate or severe hepatic failure. Childn. Elderly.
Sign Out
